title: Phase IIA trial testing erlotinib as an intervention against intraductal pancreatic mucinous neoplasms.
abstract: Intraductal papillary mucinous neoplasms (IPMN) are a distinct type of precursor lesions that cause about 5% of pancreatic adenocarcinoma (1, 2). Four-year survival rates of 40% to 75% are reported (3-7). There is currently no chemotherapy specifically approved for treating IPMNs. The number of IPMN cases has significantly increased over the last decade (8).
authors.affiliation: Department of Medicine and Chao Family NCI Designated Comprehensive Cancer Center, University of California Irvine, Irvine, California, USA. stl2012@med.cornell.edu
authors.forename: Steven
authors.initials: S
authors.lastname: Lipkin
authors.forename: John
authors.initials: J
authors.lastname: Lee
authors.forename: David
authors.initials: D
authors.lastname: Imagawa
authors.forename: Stephen M
authors.initials: SM
authors.lastname: Hewitt
authors.forename: Chris
authors.initials: C
authors.lastname: Tucker
authors.forename: Jason A
authors.initials: JA
authors.lastname: Zell
authors.forename: Vanessa
authors.initials: V
authors.lastname: Wong
authors.forename: Angela
authors.initials: A
authors.lastname: Garcia
authors.forename: Rachel
authors.initials: R
authors.lastname: Gonzalez
authors.forename: Gary
authors.initials: G
authors.lastname: Della Zanna
authors.forename: Ellen
authors.initials: E
authors.lastname: Richmond
authors.forename: L M
authors.initials: LM
authors.lastname: Rodriguez
authors.forename: M
authors.initials: M
authors.lastname: Bigg
authors.forename: F
authors.initials: F
authors.lastname: Schnoll-Sussmans
authors.forename: Frank
authors.initials: F
authors.lastname: Meyskens
mesh_terms: D002288:Adenocarcinoma, Mucinous / Q000188:drug therapy*; D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D021441:Carcinoma, Pancreatic Ductal / Q000188:drug therapy*; D000069347:Erlotinib Hydrochloride; D006801:Humans; D008297:Male; D008875:Middle Aged; D055271:Mucin 5AC / Q000096:biosynthesis / Q000187:drug effects; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D011799:Quinazolines / Q000493:pharmacokinetics / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; C524678:MUC5AC protein, human; D055271:Mucin 5AC; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride